Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - AccuredShares IssuedShares OutstandingShares Outstanding
Ratios

Zentalis Pharmaceuticals (ZNTL) Other Gross PP&E Adjustments (2021 - 2026)

Zentalis Pharmaceuticals has reported Other Gross PP&E Adjustments over the past 6 years, most recently at -$20.0 million for Q1 2026.

  • For Q1 2026, Other Gross PP&E Adjustments rose 23.95% year-over-year to -$20.0 million; the TTM value through Mar 2026 reached -$20.0 million, up 23.95%, while the annual FY2025 figure was -$27.5 million, 8.41% up from the prior year.
  • Other Gross PP&E Adjustments for Q1 2026 was -$20.0 million at Zentalis Pharmaceuticals, up from -$27.5 million in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at -$20.0 million in Q1 2026 and troughed at -$35.1 million in Q4 2022.
  • A 5-year average of -$28.2 million and a median of -$27.2 million in 2023 define the central range for Other Gross PP&E Adjustments.
  • Biggest five-year swings in Other Gross PP&E Adjustments: fell 4.43% in 2025 and later rose 23.95% in 2026.
  • Year by year, Other Gross PP&E Adjustments stood at -$35.1 million in 2022, then grew by 5.01% to -$33.3 million in 2023, then rose by 9.88% to -$30.1 million in 2024, then grew by 8.41% to -$27.5 million in 2025, then rose by 27.24% to -$20.0 million in 2026.
  • Business Quant data shows Other Gross PP&E Adjustments for ZNTL at -$20.0 million in Q1 2026, -$27.5 million in Q4 2025, and -$24.6 million in Q3 2025.